Share of Amgen (AMGN) are down $14.58, or 5%, to $274.75 in afternoon trading after the company announced full results from Part 1 of the Phase 2 study of MariTide, a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to about 20% average weight loss in people living with obesity without Type 2 diabetes compared with 2.6% in the placebo arm, and up to about 17% average weight loss in people living with obesity with T2D, compared with 1.4% in the placebo arm, per the efficacy estimand, the company reported.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen says MariTide demonstrated up to 20% average weight loss in Phase 2 study
- Amgen to present Phase 2 Maritide data at ADA meeting
- Amgen’s Strong Growth Potential and Strategic Initiatives Support Buy Rating
- Amgen’s Resilience and Growth Potential: Strong Revenue, Promising Pipeline, and Positive Outlook
- Amgen presents new interim results from the global Phase 3 DeLLphi-304 trial